Healthcare / Medical DevicesShanghai
$31.86
-1.44 (-4.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $92.8M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.6B
P/E
29.5x
↑EV/EBITDA
18.0x
↑ROE
8.4%
↑Gross Margin
59.1%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.6%
FCF CAGR
+100.4%
FCF margin
21.3%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $435.8M · net income $116.5M · FCF $92.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $435.8M | $435.8M | $468.7M | $483.8M | $380.8M |
| Net Income | $116.5M | $116.5M | $140.5M | $146.5M | $105.8M |
| EBITDA | $142.6M | $142.6M | $172.0M | $158.2M | $125.8M |
| EPS | 1.04 | 1.04 | 1.26 | 1.33 | 0.94 |
| Gross Margin | 59.1% | 59.1% | 59.0% | 58.1% | 59.3% |
| Operating Margin | 23.0% | 23.0% | 23.9% | 27.1% | 20.4% |
| Net Margin | 26.7% | 26.7% | 30.0% | 30.3% | 27.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Current Ratio | 10.21 | 10.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $92.8M | $92.8M | $131.8M | $51.9M | $11.5M |
| Returns | |||||
| ROE | 8.4% | 8.4% | 9.9% | 10.7% | 8.1% |
| Valuation | |||||
| P/E | 29.50 | 29.50 | 18.64 | 25.94 | 40.40 |
| EV/EBITDA | 17.98 | 17.98 | 9.54 | 19.73 | 30.49 |
| P/B | 2.58 | 2.58 | 1.84 | 2.78 | 3.26 |
| Growth & Yield | |||||
| Revenue Growth | -7.0% | -7.0% | -3.1% | 27.0% | — |
| EPS Growth | -17.5% | -17.5% | -5.3% | 41.5% | — |
| Dividend Yield | 3.9% | 3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
39.6%
EPS terminal req.
$2.83
Spread vs growth
-57.0%
5Y implied EPS CAGR
26.9%
EPS terminal req.
$3.42
Spread vs growth
-44.3%
10Y implied EPS CAGR
18.1%
EPS terminal req.
$5.51
Spread vs growth
-35.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.8%
Start / end P/E
23.0x → 30.6x
EPS bridge
1.26 → 1.04
Residual
-5.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.